Prof. Florent Malard- The First microbiota therapy approved by the US FDA By efrat|2022-12-06T11:42:16+00:00December 6th, 2022|All|Comments Off on Prof. Florent Malard- The First microbiota therapy approved by the US FDA Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail About the Author: efrat Related Posts Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD
